Dr. Charles Geyer reviews SABCS 2025 results using a multimodality AI model to reanalyze the NSABP B-20 trial. He highlights how AI-derived scores may help assess distant-recurrence risk and explore chemotherapy benefit, with potential for broad clinical applicability.
